Search

Your search keyword '"E. Asano"' showing total 39 results
Start Over Author "E. Asano" Topic medicine.medical_specialty
39 results on '"E. Asano"'

1. Budget Impact Analysis of the Introduction of New Therapeutic Agents for the Treatment of Metastatic Castration Resistant Prostate Cancer (MCRPC) Patients After Docetaxel Failure in the Brazilian Private Health System

Author

V. Vitale and E. Asano

Subjects
Oncology, medicine.medical_specialty, business.industry, Health Policy, MEDLINE, Public Health, Environmental and Occupational Health, Budget impact, Castration resistant, medicine.disease, Prostate cancer, Docetaxel, Internal medicine, Medicine, business, health care economics and organizations, medicine.drug
Published
2016

2. Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system

Author

E Asano, E. Barbosa, Bonnie Donato, E. Rahal, R Rached, Marcelo Eidi Nita, Eliane Ribeiro, Maíra Libertad Soligo Takemoto, and Freddy G. Eliaschewitz

Subjects
pharmacy and therapeutics committee, Male, diabetes mellitus type 2, medicine.medical_specialty, Cost effectiveness, Cost-Benefit Analysis, Adamantane, Context (language use), Rosiglitazone, health management, therapeutics, medicine, Humans, Hypoglycemic Agents, cost-effectiveness assessment, Reimbursement, General Environmental Science, Health economics, Pioglitazone, Health management system, business.industry, Dipeptides, General Medicine, Middle Aged, Metformin, Diabetes Mellitus, Type 2, Emergency medicine, General Earth and Planetary Sciences, Drug Therapy, Combination, Female, Private Sector, Thiazolidinediones, business, medicine.drug
Abstract

Summary Objectives To compare costs and clinical benefits of three additional therapies to metformin (MF) for patients with diabetes mellitus type 2 (DM2). Methods A discrete event simulation model was built to estimate the cost-utility ratio (cost per quality-adjusted life years [QALY]) of saxagliptine as an additional therapy to MF when compared to rosiglitazone or pioglitazone. A budget impact model (BIM) was built to simulate the economic impact of saxagliptine use in the context of the Brazilian private health system. Results The acquiring medication costs for the hypothetical patient group analyzed in a time frame of three years were R$ 10,850,185, R$ 14,836,265 and R$ 14,679,099 for saxagliptine, pioglitazone and rosiglitazone, respectively. Saxagliptine showed lower costs and greater effectiveness in both comparisons, with projected savings for the first three years of R$ 3,874 and R$ 3,996, respectively. The BIM estimated cumulative savings of R$ 417,958 with the repayment of saxagliptine in three years from the perspective of a health plan with 1,000,000 covered individuals. Conclusion From the perspective of private paying source, the projection is that adding saxagliptine with MF save costs when compared with the addition of rosiglitazone or pioglitazone in patients with DM2 that have not reached the HbA1c goal with metformin monotherapy. The BIM of including saxagliptine in the reimbursement lists of health plans indicated significant savings on the three-year horizon.

Published
2012
Full Text
View/download PDF

3. POSTER VIEWING SESSION - EMBRYOLOGY

Author

S. Fourati Ben Mustapha, M. Khrouf, K. Kacem Ben Rejeb, H. Elloumi Chaabene, G. Merdassi, D. Wahbi, M. Ben Meftah, F. Zhioua, A. Zhioua, A. Azzarello, T. Host, A. L. Mikkelsen, C. P. Theofanakis, V. Dinopoulou, D. Mavrogianni, G. A. Partsinevelos, P. Drakakis, K. Stefanidis, A. Bletsa, D. Loutradis, L. Rienzi, A. Cobo, A. Paffoni, C. Scarduelli, A. Capalbo, N. Garrido, J. Remohi, G. Ragni, F. M. Ubaldi, R. Herrer, M. Quera, E. GIL, J. Serna, M. L. Grondahl, J. Bogstad, I. E. Agerholm, J. G. Lemmen, U. Bentin-Ley, P. Lundstrom, U. S. Kesmodel, M. Raaschou-Jensen, S. Ladelund, L. Guzman, C. Ortega, F. K. Albuz, R. B. Gilchrist, P. Devroey, J. Smitz, M. De Vos, M. Bielanska, M. C. Leveille, E. Borghi, M. C. Magli, M. J. Figueroa, G. Mascaretti, A. P. Ferraretti, L. Gianaroli, E. Szlit, F. Leocata Nieto, G. Maggiotto, G. Arenas, N. Tarducci Bonfiglio, A. Ahumada, R. Asch, R. Sciorio, N. Dayoub, J. Thong, S. Pickering, J. Ten, M. A. Carracedo, J. Guerrero, A. Rodriguez-Arnedo, J. Llacer, R. Bernabeu, C. Tatone, T. Heizenrieder, G. Di Emidio, P. Treffon, T. Seidel, U. Eichenlaub-Ritter, S. S. Cortezzi, E. C. Cabral, C. R. Ferreira, M. G. Trevisan, R. C. S. Figueira, D. P. A. F. Braga, M. N. Eberlin, A. Iaconelli Jr., E. Borges Jr., A. Zabala, T. Pessino, L. Blanco, G. Rey Valzacchi, F. Leocata, F. Vanden Meerschaut, B. Heindryckx, C. Qian, D. Deforce, L. Leybaert, P. De Sutter, M. De las Heras, J. L. De Pablo, B. Navarro, J. A. Agirregoikoa, G. Barrenetxea, M. Cruz, I. Perez-Cano, B. Gadea, J. Herrero, M. Martinez, M. Roldan, M. Munoz, A. Pellicer, M. Meseguer, N. Galindo, F. Scarselli, E. Alviggi, A. Colasante, M. G. Minasi, P. Rubino, M. Lobascio, S. Ferrero, K. Litwicka, M. T. Varricchio, P. Giannini, P. Piscitelli, G. Franco, D. Zavaglia, Z. P. Nagy, E. Greco, F. Urner, D. Wirthner, F. Murisier, P. Mock, M. Germond, B. Amorocho Llanos, G. Calderon, D. Lopez, L. Fernandez, M. Nicolas, J. Landeras, S. L. Finn-Sell, R. Leandri, T. P. Fleming, N. S. Macklon, Y. C. Cheong, J. J. Eckert, J. H. Lee, Y. J. Jung, H. K. Hwang, A. Kang, S. J. An, J. Y. Jung, H. C. Kwon, S. J. Lee, S. Palini, L. Zolla, S. De Stefani, V. Scala, A. D'Alessandro, V. Polli, P. Rocchi, A. Tiezzi, E. Pelosi, L. Dusi, C. Bulletti, R. Fadini, M. Lain, M. Mignini Renzini, F. Brambillasca, G. Coticchio, M. Merola, M. C. Guglielmo, M. Dal Canto, R. Figueira, A. S. Setti, K. C. Worrilow, C. D. Uzochukwu, S. Eid, S. Le Gac, T. C. Esteves, F. van Rossem, A. van den Berg, M. Boiani, E. Kasapi, Y. Panagiotidis, M. Goudakou, A. Papatheodorou, T. Pasadaki, N. Prapas, Y. Prapas, P. Vanderzwalmen, S. Norasing, P. Atchajaroensatit, W. Tawiwong, O. Thepmanee, S. Saenlao, J. Aojanepong, P. Hunsajarupan, K. Sajjachareonpong, P. Punyatanasakchai, S. Maneepalviratn, U. Jetsawangsri, A. Tejera, I. Rubio, J. L. Romero, V. Nordhoff, S. Schlatt, A. N. Schuring, L. Kiesel, S. Kliesch, R. Azambuja, L. Okada, V. Lazzari, L. Dorfman, J. Michelon, M. Badalotti, F. Badalotti, A. Petracco, C. Schwarzer, K. Versieren, I. De Croo, S. Lierman, W. De Vos, E. Van den Abbeel, J. Gerris, I. Milacic, D. Borogovac, M. Veljkovic, B. Arsic, D. Jovic Bojovic, D. Lekic, D. Pavlovic, E. Garalejic, D. F. Albertini, E. De Ponti, F. Sanges, R. Talevi, L. Papini, V. Mollo, L. F. Rienzi, R. Gualtieri, C. Orteg, J. Choi, H. Lee, S. Ku, S. Kim, Y. Choi, J. Kim, S. Moon, E. Demilly, S. Assou, S. Moussaddykine, H. Dechaud, S. Hamamah, T. Takisawa, M. Doshida, H. Hattori, Y. Nakamura, T. Kyoya, Y. Shibuya, Y. Nakajo, A. Tasaka, M. Toya, K. Kyono, S. Novo, O. Penon, R. Gomez, L. Barrios, M. Duch, J. Santalo, J. Esteve, C. Nogues, J. A. Plaza, L. Perez-Garcia, E. Ibanez, S. Chavez, K. Loewke, B. Behr, R. Reijo Pera, S. Huang, H. Wang, Y. Soong, C. Chang, T. Okimura, M. Kuwayama, C. Mori, M. Morita, K. Uchiyama, F. Aono, K. Kato, Y. Takehara, O. Kato, M. Minasi, V. Casciani, L. Arizzi, C. Mencacci, C. Piscitelli, F. Cucinelli, A. Tocci, E. Wydooghe, L. Vandaele, J. Dewulf, A. Van Soom, J. H. Moon, W. Y. Son, A. Mahfoudh, S. Henderson, S. G. Jin, E. Shalom-Paz, M. Dahan, H. Holzer, K. Mahmoud, C. Triki-Hmam, K. Terras, T. Hfaiedh, M. H. Ben Aribia, H. Otsubo, A. Egashira, K. Tanaka, T. Matsuguma, M. Murakami, K. Murakami, M. Otsuka, N. Yoshioka, Y. Araki, T. Kuramoto, J. G. Smit, M. D. Sterrenburg, M. J. C. Eijkemans, H. G. Al-Inany, M. A. F. M. Youssef, F. J. M. Broekmans, K. Willoughby, L. DiPaolo, L. Deys, A. Lagunov, S. Amin, M. Faghih, E. Hughes, M. Karnis, F. Ashkar, W. A. King, M. S. Neal, I. Antonova, L. Veleva, L. Petkova, A. Shterev, C. Nogales, E. Martinez, M. Ariza, D. Cernuda, M. Gaytan, A. Linan, A. Guillen, F. Bronet, V. Cottin, D. Fabian, F. Allemann, A. Koller, J. C. Spira, D. Agudo, M. Martinez-Burgos, A. Arnanz, N. Basile, A. Rodriguez, Y. S. Cho, M. Filioli Uranio, B. Ambruosi, M. S. Paternoster, P. Totaro, A. M. Sardanelli, M. E. Dell'Aquila, U. Zollner, T. Hofmann, K. P. Zollner, B. Kovacic, P. Roglic, V. Vlaisavljevic, M. Sole, M. Boada, B. Coroleu, A. Veiga, G. Martiny, M. Molinari, A. Revelli, N. M. Chimote, M. Chimote, B. Mehta, N. N. Chimote, N. Sheikh, N. Nath, A. Mukherjee, K. Rakic, M. Reljic, H. J. Ingerslev, K. Kirkegaard, J. Hindkjaer, I. Agerholm, H. Kitasaka, N. Fukunaga, R. Nagai, T. Yoshimura, F. Tamura, K. Kitamura, N. Hasegawa, K. Nakayama, M. Katou, F. Itoi, E. Asano, N. Deguchi, K. Ooyama, Y. Hashiba, Y. Asada, M. Michaeli, N. Rotfarb, E. Karchovsky, O. Ruzov, R. Atamny, K. Slush, O. Fainaru, A. Ellenbogen, S. Chekuri, T. Chaisrisawatsuk, P. Chen, M. Pangestu, S. Jansen, S. Catt, E. Molinari, C. Racca, C. Ryu, S. Kang, J. Lee, D. Chung, S. Roh, H. Chi, Y. Yokota, M. Yokota, H. Yokota, S. Sato, M. Nakagawa, M. Komatsubara, M. Makita, K. Oyama, K. Naruse, S. Kilani, M. G. Chapman, M. Kwik, M. Chapman, S. Guven, E. Odaci, O. Yildirim, C. Kart, M. A. Unsal, E. Yulug, E. Isachenko, R. Maettner, E. Strehler, V. Isachenko, K. Hancke, R. Kreienberg, K. Sterzik, X. Y. Zheng, L. N. Wang, P. Liu, J. Qiao, F. Inoue, M. Dashtizad, H. Wahid, Y. Rosnina, M. Daliri, H. Hajarian, M. Akbarpour, O. Abbas Mazni, K. Knez, T. Tomaevic, E. Vrtacnik Bokal, B. Zorn, I. Virant Klun, M. Koster, J. Liebenthron, A. Nicolov, K. van der Ven, H. van der Ven, M. Montag, M. Fayazi, M. Salehnia, M. Beigi Boroujeni, B. Khansarinejad, K. Deignan, G. Emerson, E. Mocanu, J. J. Wang, M. Andonov, E. Linara, K. K. Ahuja, S. Nachef, F. F. Pasqualotto, E. Pasqualotto, C. C. Chang, D. P. Bernal, T. A. Elliott, D. B. Shapiro, A. A. Toledo, K. Economou, S. Davies, M. Argyrou, S. Doriza, P. Sisi, M. Moschopoulou, A. Karagianni, C. Mendorou, N. Polidoropoulos, C. Papanicopoulos, P. Stefanis, C. Karamalegos, H. Cazlaris, M. Koutsilieris, M. Mastrominas, S. Gotts, A. Doshi, J. Harper, P. Serhal, A. Borini, O. Guzeloglu-Kayisli, V. Bianchi, E. Seli, M. Lappi, M. A. Bonu, S. Mizuta, H. Hashimoto, Y. Kuroda, Y. Matsumoto, Y. Mizusawa, S. Ogata, S. Yamada, S. Kokeguchi, Y. Noda, M. Shiotani, M. Stojkovic, M. Ilic, N. Markovic, P. Stojkovic, G. Feng, B. Zhang, H. Zhou, L. Zhou, X. Gan, X. Qin, J. Shu, F. Wu, I. Molina Botella, E. Lazaro Ibanez, A. Debon Aucejo, J. Pertusa, P. J. Fernandez Colom, C. Li, Y. Zhang, Y. Cui, H. Zhao, J. Liu, J. B. A. Oliveira, C. G. Petersen, A. L. Mauri, F. C. Massaro, L. F. I. Silva, J. Ricci, M. Cavagna, A. Pontes, L. D. Vagnini, R. L. R. Baruffi, J. G. Franco Jr., V. Felipe, M. Vilela, M. Tiveron, C. Lombardi, M. I. Viglierchio, G. Marconi, V. Rawe, P. L. Wale, D. K. Gardner, K. Nakagawa, R. Sugiyama, Y. Nishi, Y. Kuribayashi, H. Jyuen, E. Yamashiro, A. Shirai, M. Inoue, O. Hovatta, V. Tohonen, J. Inzunza, L. Parmegiani, G. E. Cognigni, S. Bernardi, W. Ciampaglia, F. E. Infante, C. Tabarelli de Fatis, P. Pocognoli, A. Arnone, A. M. Maccarini, E. Troilo, M. Filicori, P. Radwan, I. Polac, M. Borowiecka, M. Bijak, and M. Radwan

Subjects
medicine.medical_specialty, Reproductive Medicine, Embryology, Rehabilitation, medicine, Obstetrics and Gynecology, Medical physics, Session (computer science), Psychology
Published
2011
Full Text
View/download PDF

4. Budget Impact Analysis of Ustekinumab for the Treatment of Moderate to Severe Crohn’s Disease from a Brazilian Private Payer Perspective

Author

E Asano, CO Fioratti, and RP Rosim

Subjects
Moderate to severe, medicine.medical_specialty, Crohn's disease, business.industry, Health Policy, Perspective (graphical), Public Health, Environmental and Occupational Health, Budget impact, medicine.disease, Ustekinumab, medicine, Intensive care medicine, business, medicine.drug
Published
2018
Full Text
View/download PDF

5. COST-MINIMIZATION ANALYSES OF BIOLOGICAL THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS UNDER THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE

Author

E Asano, L. Scaccabarozzi, and A.C. Monteiro

Subjects
medicine.medical_specialty, Biological therapies, business.industry, Health Policy, Public health, Perspective (graphical), Public Health, Environmental and Occupational Health, Alternative medicine, medicine.disease, Rheumatoid arthritis, medicine, Physical therapy, Intensive care medicine, business
Published
2016
Full Text
View/download PDF

6. Treatment Sequencing for Patients With Multiple Myeloma with at Least One Prior Line: Comparing Progression-Free Survival and Costs Under a Private Payer Perspective

Author

E Asano, A Maiolino, and E Martins

Subjects
medicine.medical_specialty, business.industry, Health Policy, Perspective (graphical), Public Health, Environmental and Occupational Health, medicine, Progression-free survival, Line (text file), Intensive care medicine, medicine.disease, business, Multiple myeloma
Published
2017
Full Text
View/download PDF

7. Treatment Patterns and Costs Associated with Chronic Lymphocytic Leukemia Chemotherapy Under the Brazilian Private Health Care Perspective: A Retrospective Analysis of the Orizon Database

Author

E.D.M.P. Paloni, C.F.S.D. Santana, M.L. Pereira, C.N. Ferreira, and E. Asano

Subjects
Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, Chronic lymphocytic leukemia, Health Policy, Perspective (graphical), Public Health, Environmental and Occupational Health, medicine.disease, Health care, medicine, Retrospective analysis, Intensive care medicine, business
Published
2013
Full Text
View/download PDF

9. Budget Impact Analysis Of The Introduction Of Darunavir 800 Mg Qd For The 2nd Line Treatment Of Hiv-Infected Treatment-Experienced Adults On The Brazilian National Hiv Program

Author

Jorge Alexandre Barbosa Neves, RG Loureiro, KA Ferreira, L.A. Magno, and E Asano

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Human immunodeficiency virus (HIV), Budget impact, medicine.disease_cause, Treatment experienced, Hiv infected, medicine, Operations management, Line (text file), business, Darunavir, medicine.drug
Published
2016
Full Text
View/download PDF

10. COST-MINIMIZATION ANALYSIS OF TNF INHIBITORS IN THE TREATMENT OF SPONDYLOARTHRITIS (PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS) UNDER THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE

Author

L. Scaccabarozzi, E Asano, and A.C. Monteiro

Subjects
Ankylosing spondylitis, medicine.medical_specialty, business.industry, Health Policy, Public health, Perspective (graphical), Public Health, Environmental and Occupational Health, medicine.disease, Psoriatic arthritis, Cost-minimization analysis, medicine, Tumor necrosis factor alpha, business, Intensive care medicine
Published
2016
Full Text
View/download PDF

11. BUDGET IMPACT ANALYSIS OF THE INCORPORATION OF GOLIMUMAB AS AN ADDITIONAL TREATMENT OPTION FOR NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

Author

E Asano, L. Scaccabarozzi, and T.B. Guimarães

Subjects
medicine.medical_specialty, Ankylosing spondylitis, business.industry, Health Policy, Public health, Public Health, Environmental and Occupational Health, Alternative medicine, Treatment options, Budget impact, medicine.disease, Golimumab, Therapy naive, medicine, Physical therapy, business, medicine.drug
Published
2016
Full Text
View/download PDF

12. Budget Impact Comparison of Abiraterone Acetate Plus Prednisone in the Pre-Chemotherapy Setting Followed by Enzalutamide in the Post-Chemotherapy Setting Versus the Opposite Treatment Sequence in Metastatic Castration-Resistant Prostate Cancer Patients Under the Brazilian Private Health Care System Perspective

Author

L. Pititto and E Asano

Subjects
Oncology, Gynecology, Chemotherapy, medicine.medical_specialty, business.industry, Health Policy, medicine.medical_treatment, Public Health, Environmental and Occupational Health, Abiraterone acetate, Budget impact, Castration resistant, medicine.disease, chemistry.chemical_compound, Prostate cancer, chemistry, Prednisone, Internal medicine, Health care, Medicine, Enzalutamide, business, medicine.drug
Published
2016
Full Text
View/download PDF

13. Budget Impact Analysis of the Incorporation of Ibrutinib for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia in the Brazilian Private Health Care System

Author

H Paiva and E Asano

Subjects
medicine.medical_specialty, business.industry, Health Policy, Chronic lymphocytic leukemia, Public Health, Environmental and Occupational Health, Budget impact, medicine.disease, chemistry.chemical_compound, chemistry, Ibrutinib, Relapsed refractory, Health care, medicine, Intensive care medicine, business
Published
2016
Full Text
View/download PDF

14. COST-MINIMIZATION ANALYSIS OF BIOLOGICAL DRUGS IN THE TREATMENT OF SPONDYLOARTHRITIS (PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS) UNDER THE BRAZILIAN PRIVATE HEALTH SYSTEM PERSPECTIVE

Author

A.C. Monteiro, L. Scaccabarozzi, and E Asano

Subjects
Biological drugs, Ankylosing spondylitis, medicine.medical_specialty, Psoriatic arthritis, business.industry, Health Policy, Perspective (graphical), Cost-minimization analysis, Public Health, Environmental and Occupational Health, medicine, medicine.disease, business, Intensive care medicine
Published
2016
Full Text
View/download PDF

15. Incidence Rates Of Patients Starting Treatment For Chronic Lymphocytic Leukemia In The Brazilian Public Health Care System: A Retrospective Epidemiologic Study Based On Datasus

Author

E Asano and H Paiva

Subjects
medicine.medical_specialty, Epidemiologic study, business.industry, Health Policy, Chronic lymphocytic leukemia, Public Health, Environmental and Occupational Health, Medicine, business, Intensive care medicine, medicine.disease, System a, Public health care
Published
2016
Full Text
View/download PDF

16. Custo-efetividade e impacto orçamentário da saxagliptina como terapia adicional à metformina para o tratamento do diabetes mellitus tipo 2 no sistema de saúde suplementar do Brasil

Author

E Asano, Eliane Ribeiro, Bonnie Donato, Freddy G. Eliaschewitz, E. Barbosa, Marcelo Eidi Nita, E. Rahal, Maíra Libertad Soligo Takemoto, and R Rached

Subjects
Health plan, pharmacy and therapeutics committee, medicine.medical_specialty, Pediatrics, diabetes mellitus type 2, Context (language use), Economia da saúde, terapêutica, medicine, health management, therapeutics, avaliação de custo-efetividade, health economics, In patient, cost-effectiveness assessment, Patient group, comitê de farmácia e terapêutica, Reimbursement, gestão em saúde, business.industry, diabetes mellitus tipo 2, General Medicine, Budget impact, economia da saúde, Surgery, business, Rosiglitazone, Health economics, Pioglitazone, medicine.drug
Abstract

OBJETIVOS: Comparar custos e benefícios clínicos de três terapias adicionais à metformina (MF) para pacientes com diabetes mellitus tipo 2 (DMT2). MÉTODOS: Um modelo de simulação de eventos discretos foi construído para estimar a relação custo-utilidade (custo por QALY) da saxagliptina como uma terapia adicional à MF comparada à rosiglitazona ou pioglitazona. Um modelo de impacto orçamentário (BIM - Budget Impact Model) foi construído para simular o impacto econômico da adoção de saxagliptina no contexto do Sistema Suplementar de Saúde brasileiro. RESULTADOS: O custo de aquisição da medicação para o grupo de pacientes hipotéticos analisados, para o horizonte temporal de três anos, foi de R$ 10.850.185,00, R$ 14.836.265,00 e R$ 14.679.099,00 para saxagliptina, pioglitazona e rosiglitazona, respectivamente. Saxagliptina exibiu menores custos e maior efetividade em ambas as comparações, com economias projetadas para os três primeiros anos de -R$ 3.874,00 e -R$ 3.996,00, respectivamente. O BIM estimou uma economia cumulativa de R$ 417.958,00 com o reembolso da saxagliptina em três anos a partir da perspectiva de uma operadora de plano de saúde com 1 milhão de vidas cobertas. CONCLUSÃO: Da perspectiva da fonte pagadora privada, a projeção é de que o acréscimo de saxagliptina à MF poupe custos quando comparado ao acréscimo de rosiglitazona ou pioglitazona em pacientes com DMT2 que não atingiram a meta de hemoglobina glicada (HbA1c) com metformina em monoterapia. O BIM, para a inclusão de saxagliptina nas listas de reembolso das operadoras de planos de saúde, indicou uma economia significativa para o horizonte de 3 anos. OBJECTIVES: To compare costs and clinical benefits of three additional therapies to metformin (MF) for patients with diabetes mellitus type 2 (DM2). METHODS: A discrete event simulation model was built to estimate the cost-utility ratio (cost per quality-adjusted life years [QALY]) of saxagliptine as an additional therapy to MF when compared to rosiglitazone or pioglitazone. A budget impact model (BIM) was built to simulate the economic impact of saxagliptine use in the context of the Brazilian private health system. RESULTS: The acquiring medication costs for the hypothetical patient group analyzed in a time frame of three years, were R$ 10,850,185, R$ 14,836,265 and R$ 14,679,099 for saxagliptine, pioglitazone and rosiglitazone, respectively. Saxagliptine showed lower costs and greater effectiveness in both comparisons, with projected savings for the first three years of R$ 3,874 and R$ 3,996, respectively. The BIM estimated cumulative savings of R$ 417,958 with the repayment of saxagliptine in three years from the perspective of a health plan with 1,000,000 covered individuals. CONCLUSION: From the perspective of private paying source, the projection is that adding saxagliptine with MF save costs when compared with the addition of rosiglitazone or pioglitazone in patients with DM2 that have not reached the HbA1c goal with metformin monotherapy. The BIM of including saxagliptine in the reimbursement lists of health plans indicated significant savings on the three-year horizon.

Published
2012

17. PUK10 KIT73 STUDY: RELATIONSHIP BETWEEN COSTS OF CARE AND 12-MONTH GLOMERULAR FILTRATION RATES IN POST-KIDNEY TRANSPLANT PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS)

Author

E. Barbosa, Marcelo Eidi Nita, E Asano, Shelagh M. Szabo, J.F. Carvalho, A.M. Nishikawa, Elias David-Neto, R.M. Esmeraldo, E. Rahal, Bonnie M.K. Donato, and Adrian R. Levy

Subjects
medicine.medical_specialty, business.industry, Health Policy, medicine, Public Health, Environmental and Occupational Health, Renal function, Intensive care medicine, business, Kidney transplant, Public health care
Published
2011
Full Text
View/download PDF

18. PCN125 MELODY BRASIL: TREATMENT PATTERNS AND ASSOCIATED COSTS OF METASTATIC MELANOMA PATIENTS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)

Author

Bonnie M.K. Donato, E Asano, S.D. Stefani, E. Rahal, Marcelo Eidi Nita, A.M. Nishikawa, K.M. Dias, and R.A. Schmerling

Subjects
Oncology, medicine.medical_specialty, Metastatic melanoma, business.industry, Public health, Internal medicine, Health Policy, medicine, Public Health, Environmental and Occupational Health, business, Surgery
Published
2011
Full Text
View/download PDF

19. PO175 SITAGLIPTIN IMPROVES DAILY GLUCOSE FLUCTUATION IN JAPANESE TYPE 2 DIABETIC OUTPATIENTS INADEQUATELY CONTROLLED WITH INSULIN THERAPY

Author

Koichi Kato, S. Sato, Jiro Nakamura, E. Takada, E. Asano, H. Nakai, Y. Sugiura, M. Motegi, C. Kojima, Atsuko Watarai, T. Hayami, Toshihito Ando, E. Naito, R. Kasagi, Yuichiro Yamada, Masaki Kondo, Yoshiro Kato, S. Noda, and Hideki Kamiya

Subjects
medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, Insulin, medicine.medical_treatment, General Medicine, medicine.disease, Endocrinology, Sitagliptin, Diabetes mellitus, Internal medicine, Internal Medicine, medicine, business, medicine.drug
Published
2014
Full Text
View/download PDF

20. PUK7 IMMUNOSUPPRESSANT THERAPY PATTERNS AND ITS COSTS IN POST KIDNEY TRANSPLANT PATIENTS IN THE NATIONAL TRANSPLANT PROGRAM IN BRAZIL

Author

Marcelo Eidi Nita, E Asano, R.C. Manfro, Bonnie M.K. Donato, F Carvalho, H.J. Tedesco-Silva, S Dan, and E. Rahal

Subjects
Nephrology, medicine.medical_specialty, business.industry, Internal medicine, Health Policy, medicine, Public Health, Environmental and Occupational Health, urologic and male genital diseases, Intensive care medicine, business, Kidney transplant
Published
2010
Full Text
View/download PDF

21. PUK21 POST-KIDNEY TRANSPLANT MORBIDITY RELATED RE-HOSPITALIZATIONS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM: CAUSES, RESOURCES USE AND COSTS BASED ON AN ADMINISTRATIVE REGISTRY REVIEW FROM 2004 TO 2009

Author

S Dan, Félix Carvalho, Elias David-Neto, Dbm Carvalho, Marcelo Eidi Nita, E Asano, E. Rahal, and Bonnie M.K. Donato

Subjects
medicine.medical_specialty, business.industry, Public health, Health Policy, medicine, Public Health, Environmental and Occupational Health, Intensive care medicine, business, Kidney transplant
Published
2010
Full Text
View/download PDF

22. PCN34 BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL

Author

R Rached, B.M.K. Donato, A Moellmann-Coelho, E Asano, E. Rahal, and Marcelo Eidi Nita

Subjects
Oncology, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Myeloid leukemia, Budget impact, Imatinib resistant, Dasatinib, Internal medicine, medicine, In patient, business, medicine.drug
Published
2009
Full Text
View/download PDF

23. Cost-Effectiveness of Canagliflozin (Cana) Versus Sitagliptin (Sita) As Add-On To Metformin Plus Sulfonylurea In Patients With Type 2 Diabetes Mellitus (T2dm) In Brazil

Author

A.R. Teschemaker, E. Asano, Michael Willis, L. Pititto, Pierre Johansen, Cheryl Neslusan, and A. Puig

Subjects
Canagliflozin, medicine.medical_specialty, Cost effectiveness, medicine.drug_class, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Type 2 Diabetes Mellitus, Sulfonylurea, Metformin, Sitagliptin, Internal medicine, medicine, In patient, business, medicine.drug
Published
2015
Full Text
View/download PDF

24. Direct Medical Costs (DMC) of Treating Chronic Lymphoid Leukemia (CLL) Patients in the Private Health Care System in Brazil: Results from a 12-Month Retrospective Analysis of an Administrative Database

Author

E.D.M.P. Paloni, C.F.S.D. Santana, E. Asano, M.L. Pereira, and C.N. Ferreira

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Chronic lymphoid leukemia, Administrative database, Health care, Emergency medicine, Retrospective analysis, Physical therapy, Medicine, business, Medical costs, health care economics and organizations
Abstract

MethOdS: The Orizon database, an administrative database containing inpatient and outpatient claims to a pool of 102 HMOs representing 34% of the total Private Health System, was reviewed from Jan/2009 to Dec/2012. Eligibility criteria were patients starting CLL (ICD-10 code C911) treatment from Apr/2009 to Dec/2011. Outcome was direct medical costs (DMC) per patient-year, calculated as the sum of the medical claims for each patient included in the analysis, for a maximum period of 12-months or death or loss of follow-up, whichever comes first. DMC was categorized in chemotherapy, hospitalizations, and other outpatient costs. Further analysis was conducted for chemotherapy and hospitalizations.

Published
2013
Full Text
View/download PDF

25. PSU29 The Importance of Medical Appointments After Roux-en-Y Gastric Bypass in Morbid Obese Patients: Association Between Adherence to Medical Follow-Up Visits and the Bariatric Analysis and Reporting Outcome System (BAROS) Score Based on an Administrative Database (DATASUS) in Brazil

Author

I. Rasera, E. Asano, E.C. Shiraga, and P.G. Cunha

Subjects
medicine.medical_specialty, Pediatrics, Administrative database, business.industry, General surgery, Health Policy, Gastric bypass, medicine, Public Health, Environmental and Occupational Health, business, Roux-en-Y anastomosis, health care economics and organizations
Published
2012
Full Text
View/download PDF

26. PCN79 IMPACT OF NON-ADHERENCE TO IMATINIB ON PROGRESSION-FREE SURVIVAL AS 1ST TREATMENT FOR CHRONIC MYELOID LEUKEMIA IN BRAZIL: TWO YEARS FOLLOW UP

Author

E. Rahal, Bonnie M.K. Donato, A Moellmann-Coelho, E Asano, V.A.M. Funke, and Marcelo Eidi Nita

Subjects
Oncology, medicine.medical_specialty, business.industry, Health Policy, Internal medicine, Public Health, Environmental and Occupational Health, medicine, Myeloid leukemia, Imatinib, Progression-free survival, business, Non adherence, medicine.drug
Published
2011
Full Text
View/download PDF

27. PUK19 KIT73: PRELIMINARY REPORTS OF IMMUNOSUPRESSANT THERAPY PATTERNS IN A COHORT OF POST KIDNEY TRANSPLANT PATIENTS IN BRAZIL

Author

A.M. Nishikawa, E Asano, Marcelo Eidi Nita, M. Abbud-Filho, D.D.B.M. Carvalho, Shelagh M. Szabo, V. Garcia, J.F. Carvalho, Bonnie M.K. Donato, Adrian R. Levy, and E. Rahal

Subjects
medicine.medical_specialty, business.industry, Internal medicine, Health Policy, Cohort, medicine, Public Health, Environmental and Occupational Health, business, Kidney transplant, complex mixtures, health care economics and organizations
Published
2011
Full Text
View/download PDF

29. PDB13 BUDGET IMPACT ANALYSIS OF SAXAGLIPTIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 (T2D) PATIENTS IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM

Author

E Asano, P Mantilla, E Ribeiro, E. Barbosa, Bonnie M.K. Donato, A Pimentel, Marcelo Eidi Nita, R Rached, and E. Rahal

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Budget impact, Saxagliptin, medicine.disease, chemistry.chemical_compound, Endocrinology, chemistry, Family medicine, Internal medicine, Diabetes mellitus, Health care, medicine, business
Published
2010
Full Text
View/download PDF

30. PCN124 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL

Author

E Asano, R Rached, B.M.K. Donato, Marcelo Eidi Nita, E. Rahal, and A Moellmann-Coelho

Subjects
Oncology, medicine.medical_specialty, Cost–utility analysis, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Myeloid leukemia, Imatinib resistant, Dasatinib, Internal medicine, medicine, In patient, business, medicine.drug
Published
2009
Full Text
View/download PDF

32. Budget Impact Analysis of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated with Docetaxel from the Perspective of the Brazilian Private Health Care System

Author

M.L. Pereira, V. Vitale, and E. Asano

Subjects
Oncology, medicine.medical_specialty, business.industry, Health Policy, Perspective (graphical), Public Health, Environmental and Occupational Health, Abiraterone acetate, Budget impact, Castration resistant, medicine.disease, chemistry.chemical_compound, Prostate cancer, chemistry, Docetaxel, Internal medicine, Health care, Medicine, business, Previously treated, medicine.drug
Published
2013
Full Text
View/download PDF

34. PCN122 MELODY BRAZIL: CHEMOTHERAPY CHOICES FOR PATIENTS WITH METASTATIC MELANOMA IN THE PUBLIC HEALTH CARE SYSTEM (SUS)

Author

A.M. Nishikawa, Bonnie M.K. Donato, E Asano, R.A. Schmerling, Marcelo Eidi Nita, S.D. Stefani, E. Rahal, K.M. Dias, and E. Barbosa

Subjects
medicine.medical_specialty, Chemotherapy, Metastatic melanoma, business.industry, Health Policy, General surgery, medicine.medical_treatment, Public Health, Environmental and Occupational Health, medicine, business, Public health care, Surgery
Published
2011
Full Text
View/download PDF

35. PDB62 COST-UTILITY ANALYSIS OF SAXAGLIPTIN AS AN ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS FROM THE BRAZILIAN PRIVATE HEALTH SYSTEM

Author

Marcelo Eidi Nita, Bonnie M.K. Donato, R Rached, E Asano, and FG Eliaschewitz

Subjects
medicine.medical_specialty, Cost–utility analysis, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Type 2 diabetes, Saxagliptin, medicine.disease, Metformin, Add on therapy, chemistry.chemical_compound, chemistry, Medicine, business, Intensive care medicine, medicine.drug
Published
2010
Full Text
View/download PDF

36. PDB14 HOSPITALIZATION ATTRIBUTED TO DIABETES MELLITUS AND ITS COMPLICATIONS IN THE PRIVATE HEALTH-CARE SYSTEM IN RIBEIRÃO PRETO REGION, BRAZIL

Author

Roger dos Santos Rosa, E Asano, Marcelo Eidi Nita, Luciana Bahia, Bonnie M.K. Donato, and R Monteiro

Subjects
medicine.medical_specialty, business.industry, Health Policy, Diabetes mellitus, Health care, Emergency medicine, Public Health, Environmental and Occupational Health, medicine, Medical emergency, business, medicine.disease
Published
2010
Full Text
View/download PDF

37. PUK22 REJECTION EPISODES REQUIRING HOSPITALIZATION AFTER KIDNEY TRANSPLANT IN BRAZIL: A RETROSPECTIVE DATABASE STUDY OF THE BRAZILIAN PUBLIC HEALTH SYSTEM

Author

Bonnie M.K. Donato, F Carvalho, E Asano, S Dan, V Duro-Garcia, Marcelo Eidi Nita, E. Rahal, M. Abbud-Filho, and R.M. Esmeraldo

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public health, Public Health, Environmental and Occupational Health, Medicine, business, Intensive care medicine, Kidney transplant, Retrospective database
Published
2010
Full Text
View/download PDF

39. PSU28 Variables Associated with Length of Stay and ICU Need in Roux-en-Y Gastric Bypass Surgery for Morbid Obese Patients: A Cross-Sectional Study Based on the Public Health System Database (DATASUS) in Brazil

Author

P.G. Cunha, E. Asano, E.C. Shiraga, and I. Rasera

Subjects
medicine.medical_specialty, business.industry, Gastric bypass surgery, Cross-sectional study, Public health, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease_cause, Roux-en-Y anastomosis, Emergency medicine, Medicine, business, Intensive care medicine, health care economics and organizations
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results